This study investigated the influence of drug-company funding on websites about attention-deficit hyperactivity disorder (ADHD). Websites in the top 60 for either Google or Yahoo!Xtra with information about causation and treatment were analysed. Likert scales, based on those used in previous similar studies, were developed to rate aetiological explanations and recommended treatment approaches, on a dimension from psycho-social to biological. Overall, the quality of information on websites was poor with a strong bias towards bio-genetic aetiological explanations of ADHD. Twenty-one of the 57 websites (37%) were funded by drug companies. The drug-company funded (DCF) websites were significantly more likely than non-DCF websites to recommend medication rather than psycho-social treatments. The selective lack of consideration of psycho-social treatments by DCF websites is discussed in relation to the relevant research literature, including the evidence in favour of a multimodal approach. The findings, which are consistent with previous similar studies in relation to websites about adult mental health problems, confirm that the pharmaceutical industry is seeking to influence public opinion via the internet.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders DSM-IV-TR (4th, text revision ed.). Washington, DC: American Psychiatric Association.
AngermeyerM.DietrichS. (2006). Public beliefs about and attitudes towards people with mental illness: A review of population studies. Acta Psychiatrica Scandinavica, 113, 163–179.
4.
AngermeyerM.MatschingerH. (2005). Causal beliefs and attitudes to people with schizophrenia: A trend analysis based on data from two population surveys in Germany. British Journal of Psychiatry, 186, 331–334.
5.
AntonuccioD.DantonW.McClanahanT. (2003). Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist, 58, 1028–1043.
6.
ArnoldL.ChuangS.DaviesM.AbikoffH.ConnersC.ElliottG.. (2004). Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology, 32, 39–51.
7.
ArnstenA. (1999). Development of the cerebral cortex: XIV. Stress impairs prefrontal cortical function. Journal of the American Academy of Child and Adolescent Psychiatry, 38(2), 220–222.
8.
ArnstenA. (2000). Genetics of childhood disorders: XVIII. ADHD, Part 2: Norepinephrine has a critical modulatory influence on prefrontal cortical function. Journal of the American Academy of Child and Adolescent Psychiatry, 39(9), 1201–1203.
9.
BarkleyR. (2006). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed.). New York: The Guilford Press.
10.
BauermeisterJ.ShroutP.RamirezR.BravoM.AlegriaM.Martinez-TaboasA.. (2007). ADHD correlates, comorbidity, and impairment in community and treated samples of children and adolescents. Journal of Abnormal Child Psychology, 35(6), 883–898.
11.
Becker-BleaseK.FreydJ. (2008). A preliminary study of ADHD symptoms and correlates: Do abused children differ from nonabused children?Journal of Aggression, Maltreatment & Trauma, 17(1), 133–140.
12.
BhataraV.LoudenbergR.EllisR. (2006). Association of attention deficit hyperactivity disorder and gestational alcohol exposure. Journal of Attention Disorders, 9, 515–522.
13.
Briscoe-SmithA.HinshawS. (2006). Linkages between child abuse and attention-deficit/hyperactivity disorder in girls: Behavioral and social correlates. Child Abuse & Neglect, 30(11), 1239–1255.
14.
CaronC.RutterM. (1991). Comorbidity in child psychopathology: Concepts, issues and research strategies. Journal of Child Psychology and Psychiatry, 32(7), 1063–1080.
15.
ChabotR.SerfonteinG. (1996). Quantitative electroencephalographic profiles of children with attention deficit disorder. Biological Psychiatry, 40(10), 951–963.
16.
CharachA.IckowiczA.SchacharR. (2004). Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. Journal of the American Academy of Child and Adolescent Psychiatry, 43(5), 559–567.
17.
ChronisA.ChackoA.FabianoG.WymbsB.PelhamW. (2004). Enhancements to the behavioral parent training paradigm for families of children with ADHD: Review and future directions. Clinical Child and Family Psychology Review, 7, 1–27.
18.
ClarkeL.UngererJ.ChahoudK.JohnsonS.StiefelI. (2002). Attention deficit hyperactivity disorder is associated with attachment insecurity. Clinical Child Psychology and Psychiatry, 7(2), 179–198.
19.
CorkumP.PantonR.IronsideS.MacPhersonM.WilliamsT. (2008). Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder. Journal of Pediatric Psychology, 33(4), 368–379.
20.
CosgroveL.KrimskyS.VijayaraghavanM.SchneiderL. (2006). Financial ties between DSM-IV panel members and the pharmaceutical Industry. Psychotherapy and Psychosomatics, 75, 154–160.
21.
De SanctisV.TrampushJ.HartyS.MarksD.NewcornJ.MillerC.. (2008). Childhood maltreatment and conduct disorder: Independent predictors of adolescent substance use disorders in youth with attention deficit/hyperactivity disorder. Journal of Clinical Child and Adolescent Psychology, 37(4), 785–793.
22.
de WattignarS.ReadJ. (2009). The pharmaceutical industry and the internet: Are drug-company funded depression websites biased?Journal of Mental Health, 18, 1–10.
23.
DopfnerM.BreuerD.WilleN.ErhartM.Ravens-SiebererU. (2008). How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample – results of the BELLA study. European Child & Adolescent Psychiatry, 17(Suppl 1), 59–70.
24.
EdelM-A.JuckelG.BruneM. (2010). Interaction of recalled parental ADHD symptoms and rearing behavior with current attachment and emotional dysfunction in adult offspring with ADHD. Psychiatry Research, 178, 137–141.
25.
EgleU. T.HardtJ.NickelR.KappisB.HoffmanS. O. (2002). Early stress and its long-term effects on health – state of the art and implications for future research. Z Psychosom Med Psychother, 48, 411–434.
26.
FabianoG. APelhamW. E.JrColesE. K.GnagyE.M.Chronis-TuscanoA.O’ConnorB. (2009). A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clinical Psychology Review, 29(2), 129–140.
27.
FaraoneS.GieferE. (2007). Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. Journal of the American Academy of Child and Adolescent Psychiatry, 46(9), 1138–1147.
28.
FaraoneS.KhanS. (2006). Candidate gene studies of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 67, 13–20.
GriffithsK.ChristensenH. (2000). Quality of web based information on treatment of depression: Cross sectional survey. British Medical Journal, 321, 1511–1515.
34.
HealyD.ThaseM. E. (2003). Is academic psychiatry for sale?British Journal of Psychiatry, 182, 388–390.
35.
HeneghanA.GarnerA. S.Storfer-IsserA.KortepeterK.SteinR.HorwitzS. (2008). Pediatricians’ role in providing mental health care for children and adolescents: Do pediatricians and child and adolescent psychiatrists agree?Journal of Developmental and Behavioral Pediatrics, 29, 262–269.
36.
HudziakJ.RudigerL.NealeM.HeathA.ToddR. (2000). A twin study of inattentive, aggressive, and anxious/depressed behaviors. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 469–476.
37.
JosephJ. (2006). The missing gene: Psychiatry, heredity, and the fruitless search for genes. New York: Algora.
38.
KingS.GriffinS.HodgesZ.WeatherlyH.AsseburgC.RichardsonG.. (2006). A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment, 10(23), iii–iv, xiii–146.
39.
KiselyS.OngG.TakyarA. (2003). A survey of the quality of web based information on the treatment of schizophrenia and attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry, 37(1), 85–91.
40.
KreppnerJ.O’ConnorT.RutterM. (2001). Can inattention/overactivity be an institutional deprivation syndrome?Journal of Abnormal Child Psychology, 29(6), 513–528.
41.
LamL. (2005). Attention deficit disorder and hospitalization owing to intra- and interpersonal violence among children and young adolescents. Journal of Adolescent Health, 36, 19–24.
42.
LangbergJ.EpsteinJ.UrbanowiczC.SimonJ.GrahamA. (2008). Efficacy of an organization skills intervention to improve the academic functioning of students with attention-deficit/hyperactivity disorder. School Psychology Quarterly, 23(3), 407–417.
43.
LooS.BarkleyR. (2005). Clinical utility of EEG in attention deficit hyperactivity disorder. Applied Neuropsychology, 12(2), 64–76.
44.
MansellP.ReadJ. (2009). Posttraumatic stress disorder, drug companies, and the internet. Journal of Trauma & Dissociation, 10(1), 9–23.
45.
MerryS.AndrewsL. (1994). Psychiatric status of sexually abused children 12 months after disclosure of abuse. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 939–944.
46.
MonastraV. J. (2005). Nutrition does matter. Washington, DC: American Psychological Association.
47.
MoncrieffJ. (2007). Co-opting psychiatry: The alliance between academic psychiatry and the pharmaceutical industry. Epidemiologia e Psichiatria Sociale, 16, 192–196.
48.
MoynihanR.CasselsA. (2005). Selling sickness: How the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books.
49.
MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073–1086.
50.
MTA Cooperative Group. (2004a). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics, 113, 754–761.
51.
MTA Cooperative Group. (2004b). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics, 113, 762–769.
52.
MTA Cooperative Group. (2007). 3-year follow-up of the NIMH MTA study. Journal of the American Acadamy of Child and Adolescent Psychiatry, 46(8), 989–1002.
53.
MTA Cooperative Group. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Acadamy of Child and Adolescent Psychiatry, 48(5), 484–500.
54.
OuyangL.FangX.MercyJ.PerouR.GrosseS. (2008). Attention-deficit/hyperactivity disorder symptoms and child maltreatment: A population-based study. The Journal of Pediatrics, 153(6), 851–856.
55.
PelsserL.FrankenaK.ToormanJ.SavelkoulH.PereiraR.BuitelaarJ. (2009). A randomised controlled trial into the effects of food on ADHD. European Child & Adolescent Psychiatry, 18, 12–19.
56.
PerryB. (2002). Childhood experience and the expression of genetic potential: What childhood neglect tells us about nature and nurture. Brain and Mind, 3, 79–100.
57.
PescosolidoB.FettesD.MartinJ.MonahanJ.McLeodJ. (2007). Perceived dangerousness of children with mental health problems and support for coerced treatment. Psychiatric Services, 58, 619–625.
58.
PinedaD.ArdilaA.RosselliM.AriasB.HenaoG.GomezL.. (1999). Prevalence of attention-deficit/hyperactivity disorder symptoms in 4- to 17-year-old children in the general population. Journal of Abnormal Child Psychology, 27(6), 455–462.
59.
PowellJ.ClarkeA. (2006). Internet information-seeking in mental health. British Journal of Psychiatry, 189, 273–277.
60.
QuinnD.WigalS.SwansonJ.HirschS.OttoliniY.DarianiM.. (2004). Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 43(11), 1422–1429.
61.
ReadJ. (2008). Schizophrenia, drug companies and the internet. Social Science & Medicine, 66, 99–109.
62.
ReadJ.SandersP. (2010). A straight talking introduction to the causes of mental health problems. Ross: PCCS Books.
63.
ReadJ.HarréN. (2001). The role of biological and genetic causal beliefs in the stigmatisation of “mental patients”. Journal of Mental Health, 10(2), 223–235.
64.
ReadJ.HaslamN.SayceL.DaviesE. (2006). Prejudice and schizophrenia: A review of the ‘mental illness is an illness like any other’ approach. Acta Psychiatrica Scandinavica, 114, 303–318.
65.
RelmanA.AngellM. (2002). America’s other drug problem: How the drug industry distorts medicine and politics. The New Republic, 27–41, December16.
66.
RickelA.BrownR. (2007). Attention-deficit/hyperactivity disorder in children and adults. Cambridge, MA: Hogrefe & Huber Publishers.
67.
RosenthalM.BerndtE.DonohueJ.FrankR.EpsteinA. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346, 498–505.
68.
RucklidgeJ.BrownD.CrawfordS.KaplanB. (2006). Retrospective reports of childhood trauma in adults with ADHD. Journal of Attention Disorders, 9, 631–641.
69.
SchachterH.PhamB.KingJ.LangfordS.MoherD. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta- analysis. Canadian Medical Association Journal, 165, 1475–1488.
70.
SchefflerR.HinshawS.ModrekS.LevineP. (2007). TRENDS: The global market for ADHD medications. Health Affairs, 26, 450–457.
71.
SharfsteinS. (2005). Big Pharma and American psychiatry: The good, the bad, and the ugly. Psychiatric News, 40(16), 3–5.
72.
ShooterM. (2005). Dancing with the devil? A personal view of psychiatry’s relationships with the pharmaceutical industry. Psychiatric Bulletin, 29, 81–83.
73.
SilvaR.MunizR.PestreichL.BramsM.MaoA.ChildressA.. (2008). Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 199–208.
74.
SpencerN.DevereuxE.WallaceA.SundrumR.ShenoyM.BacchusC.LoganS. (2005). Disabling conditions and registration for child abuse and neglect: A population-based study. Pediatrics, 116(3), 609–613.
75.
SwansonJ.ArnoldL. E.KraemerH.HechtmanL.MolinaB.HinshawS.. (2008). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA). Journal of Attention Disorders, 12, 4–14.
76.
TimimiS. (2005). Naughty boys: Anti-social behaviour, ADHD and the role of culture. Basingstoke: Palgrave-Macmillan.
77.
TimimiS. (2008). Child psychiatry and its relationship with the pharmaceutical industry: Theoretical and practical issues. Advances in Psychiatric Treatment, 14, 3–9.
78.
TimimiS. (2009a). A critique of the neurodevelopmental model of attention deficit hyperactivity disorder. Thymos: The Journal of Boyhood Studies, 3, 139–144.
79.
TimimiS. (2009b). A straight-talking introduction to children’s mental health problems. Ross: PCCS Books
80.
TimimiS. (2009c). The use of psycho-pharmaceuticals to control boys’ behaviour: A tale of badly behaving drug companies and doctors. Arab Journal of Psychiatry, 20, 147–160.
81.
van den BanE.SouvereinP.SwaabH.van EngelandH.HeerdnikR.EgbertsT. (2010). Trends in incidence and characteristics of children, adolescents, and adults inititating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. Journal of Child and Adolesecent Psychopharmacology, 20 (1), 55–61.
82.
von SydowK.BeherS.Schweitzer-RothersJ.RetzlaffR. (2006). Systemic family therapy with children and adolescents as index patients: A meta-content analysis of 47 randomized controlled outcome studies. Psychotherapeutics, 51(2), 107–143.
83.
WeinsteinD.StaffelbachD.BiaggioM. (2000). Attention-deficit hyperactivity disorder and posttraumatic stress disorder: Differential diagnosis in childhood sexual abuse. Clinical Psychology Review, 20(3), 359–378.
84.
WilliamsN.ZaharievaI.MartinA.LangleyK.MantripragadaK.FossdalR.. (2010). Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: A genome-wide analysis. Lancet, 376, 1401–1408.
85.
WoodlockD. (2005). Virtual pushers: Antidepressant internet marketing and women. Women’s Studies International Forum, 28(4), 304–314.
